Cadrenal Therapeutics, Inc. (CVKD)
NASDAQ: CVKD · IEX Real-Time Price · USD
0.430
-0.010 (-2.21%)
At close: Jul 19, 2024, 4:00 PM
0.490
+0.060 (13.95%)
Pre-market: Jul 20, 2024, 9:28 AM EDT
Company Description
Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company.
The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome.
Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.
Cadrenal Therapeutics, Inc.
Country | United States |
Founded | 2022 |
IPO Date | Jan 20, 2023 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 4 |
CEO | Quang X. Pham |
Contact Details
Address: 822 A1a North, Suite 300 Ponte Vedra, Florida 32082 United States | |
Phone | 904-300-0701 |
Website | cadrenal.com |
Stock Details
Ticker Symbol | CVKD |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $5.00 |
CIK Code | 0001937993 |
ISIN Number | US1276361086 |
Employer ID | 88-0860746 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Quang X. Pham | Chairman and Chief Executive Officer |
Dr. Douglas W. Losordo FACC, FAHA, M.D. | Chief Medical Officer |
Matthew K. Szot CPA, CPA | Chief Financial Officer |
Jeffrey Cole | Chief Operating Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Jun 12, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Jun 11, 2024 | ARS | Filing |
Jun 11, 2024 | DEF 14A | Other definitive proxy statements |
May 29, 2024 | PRE 14A | Other preliminary proxy statements |
May 9, 2024 | 10-Q | Quarterly Report |
May 9, 2024 | 8-K | Current Report |
Apr 9, 2024 | 8-K | Current Report |
Apr 2, 2024 | EFFECT | Notice of Effectiveness |
Apr 2, 2024 | POS AM | Post-Effective amendments for registration statement |
Mar 20, 2024 | EFFECT | Notice of Effectiveness |